Pharmacological interventions for the treatment of Coronavirus Disease (COVID-19)

• Autores: Huaroto, Fabiola, Reyes, Nora, Huamán, Karen, Bonilla, Catherine, Curisinche-Rojas, Maricela, Carmona, Gloria, Gutierrez, Ericson, Caballero, Patricia
• Formato: artículo
• Fecha de Publicación: 2020
• Institución: Universidad Nacional Mayor de San Marcos
• Repositorio: Revistas - Universidad Nacional Mayor de San Marcos
• Lenguaje: español
• OAI Identifier: oai:ojs.csi.unmsm:article/17686
• Enlace del recurso: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/17686
• Nivel de acceso: acceso abierto
• Materia: Evaluación de Resultados de Intervenciones Terapéuticas; Infecciones por Coronavirus; Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo; Hidroxicloroquina; Lopinavir; Ritonavir; Evaluation of Results of Therapeutic Interventions; Coronavirus Infections; SARS Virus; Hydroxychloroquine

Several drugs have been proposed as therapeutic alternatives for COVID-19. An electronic systematic search of MEDLINE (via PubMed) was carried out until March 20th 2020, in order to identify the available evidence on pharmacological interventions for specific treatment of COVID-19. The quality of the evidence from clinical trials was evaluated according to the GRADE methodology. 947 publications were identified and 15 studies were selected: 3 clinical trials, 5 case series and 7 case reports. The existing evidence for hydroxychloroquine, favipiravir and lopinavir/ritonavir comes from clinical trials reporting favorable results for the first two drugs, while no benefit was observed when lopinavir/ritonavir was added to standard treatment. However, due to methodological issues, the evidence for hydroxychloroquine is very low. For favipiravir and lopinavir/ritonavir the evidence is low. Regarding the use of arbidol interferon, or the combined use of these with lopinavir/ritonavir, the evidence is limited since it derives from case series or case report with non-determining results. No studies were identified that reliably demonstrate the efficacy and safety of any pharmacological intervention against COVID-19.